ANI Pharmaceuticals, Inc. Aktie News

BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows:

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- --ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness--

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.

BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million, according to latest estimates from IQVIA/IMS Health, a leading healt...

The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks present enticing prospects for growth and value for investors willing to capitalize on calculated risks. The S&P 500 P/E is 25x vs. the S&P Small-Cap at 14.8x.

ANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call Transcript